ClinicalTrials.gg
RecruitingNCT07096778DOMMINO-1Updated Sep 21, 2026

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of Inobrodib and Pomalidomide in Multiple Myeloma Refractory and Multiple Myeloma in Relapse, sponsored by CellCentric Ltd.. Recruiting at 31 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by CellCentric Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Planned enrollment
409th of 1,901
100 · median 36
Started
2026
with 75 others
Phase 2
751 of 2,168
76 open now
Primary completion
2029-12
later than 419 of 499 live
Registered
2,089th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 409th largest by planned enrollment of the 1,901 interventional ones that give a count, is one of 76 that started in 2026, is one of 751 in phase 2, reaches primary completion later than 419 of the 499 other live ones, and was the 2,089th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Read the detailed description

This is a Phase II, open-label, multicenter study to evaluate the efficacy and safety of inobrodib in combination with pomalidomide and dexamethasone (InoPd) in patients with relapsed and refractory multiple myeloma (RRMM).

Patients must be 18 years or older and be refractory to least one proteosome inhibitor (PI), one anti-CD38 monoclonal antibody (mAb) and pomalidomide. Patients must also be previously treated with an approved bispecific T-cell engager [TCE].

Approximately 100 patients will be treated with 20 mg of inobrodib administered orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle. Pomalidomide and dexamethasone will be administered as per standard of care (SoC), i.e., with a starting dose of 4 mg orally once daily on Day 1 to 21 of each 28-day cycle for pomalidomide, and 40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle for dexamethasone. Study treatment should be continued until disease progression, initiation of new anticancer therapy, unacceptable toxicity or the patient meets any criteria for withdrawal from the study.

The primary objective is to assess the efficacy of InoPd in terms of objective response rate (ORR) based on International Myeloma Working Group (IMWG) criteria and assessed by Independent Review Committee (IRC).

03

Conditions studied

  • Multiple Myeloma Refractory
  • Multiple Myeloma in Relapse

Browse trials for

Keywords

  • Inobrodib
  • Pomalidomide
  • Pomalyst
  • Imnovid
  • Dexamethasone
  • p300-CBP Transcription Factors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age
  • Prior diagnosis of MM as defined according to IMWG criteria and to the last
  • Eastern Co-operative Oncology Group () performance status of 0 to 2
  • Adequate hematological, renal and hepatic function
  • Willingness to use highly effective measures (if sexually active) with all sexual partners

Exclusion criteria

Exclusion Criteria:

  • Use of any agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest
  • Prior treatment with p300/CBP bromodomain inhibitors
  • Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
  • Treatment with medicines or herbal supplements or foods (e.g. strong inducers or inhibitors) that would interfere with treatment
  • Major surgery within 4 weeks of the first dose of study treatment
  • within 4 weeks of study treatment
  • Active or unresolved adverse events
  • Active (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
  • Female patients who are pregnant or breast-feeding at any time during the study
  • Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Inobrodib in combination with pomalidomide and dexamethasone

    Drug: Inobrodib · Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • 20 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.

    Also known as: CCS1477

  • 4 mg orally once daily on Day 1 to 21 of each 28-day cycle

    Also known as: Pomalyst, Imnovid

  • 40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle

06

What researchers measure

Primary outcomes

  1. Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC)

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

Secondary outcomes

  1. ORR, defined as the percentage of patients with a confirmed PR or better, based on IMWG criteria assessed by Investigator

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

  2. Duration of Response (DoR), defined as the duration of overall response by investigator and IRC

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

  3. Time to Response (TTR), defined as time to confirmed PR or better, by investigator and IRC

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

  4. Very Good Partial Response (VGPR) or better rate, defined as the percentage of patients with a confirmed VGPR or better, based on IMWG criteria and assessed by investigator and IRC

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

  5. Complete Response (CR) or better rate, defined as the percentage of patients with a confirmed CR or better, based on IMWG criteria and assessed by investigator and IRC

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

  6. Progression Free Survival (PFS), defined as the time from enrolment until the earliest date of Progressive Disease (PD), or death due to any cause, and assessed by investigator and IRC

    Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)

  7. Overall Survival (OS), defined as the time from enrolment to the date of death due to any cause

    Time frame: Assessed from enrollment to date of death from any cause, until the end of study (up to 48 months)

  8. Incidence of treatment-emergent adverse events (TEAEs), vital signs and laboratory abnormalities

    Time frame: Assessed from start of treatment until 28 days after end of treatment

07

Study locations

31 of 31 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The final clinical study report will be provided to the Investigators. The Sponsor will publicly disclose study results through posting on ClinicalTrials.gov and any other applicable public registries in accordance with local regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 46 months after the start.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 46 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Jan 22, 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07096778
Lead sponsor
CellCentric Ltd.
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Jan 22, 2026
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Sep 21, 2026

Study contacts

CCS1477-04 Clinical Operations
Contact
DOMMINO-1@cellcentric.com
+44 1799 531130
Naseer Qayum
study director · CellCentric Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CCS1477

Start the discussion